Relapsed and Refractory Hematological Malignancies
Conditions
Keywords
Relapsed, Refractory, Hematological malignancy, CAR-T cells
Brief summary
This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.
Interventions
BIOLOGICALCAR-T cells
Chimeric Antigen Receptor-T cells
Sponsors
Juventas Cell Therapy Ltd.
Institute of Hematology & Blood Diseases Hospital, China
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patients suffering from a hematological malignancy that is severely life-threatening or seriously affects the patient's quality of life and has no effective treatment available, who not meet the inclusion/
Exclusion criteria
for other clinical trials in the process of subject recruitment, or who are unable to obtain other study drugs or participate in clinical studies/trials for some reason (regional or time restriction, etc., or the recruitment of subjects for clinical studies/trials has ended but the drug has not yet been approved for marketing in China); * Patients who are definitely diagnosed with the corresponding target-positive relapsed and refractory hematological malignancies, including but not limited to the following circumstances: * Patients who do not meet the inclusion/
Countries
China
Contacts
Primary ContactYing Wang, Dr.
Outcome results
None listed